4514 Results
1

From lab to legacy inside UC’s 1819 Innovation Hub

December 12, 2023

In the vibrant corridors of the University of Cincinnati, pioneering research extends beyond the confines of laboratories — it launches revolutionary ideas poised to reshape the world. The key to safeguarding these innovations lies in the swift and savvy journey through the 1819 Innovation Hub’s technology transfer and patent licensing process, a vital approach for both faculty and the university.

2

UC 1819 Innovation Hub serves as the blueprint for local real estate startup

December 12, 2023

In the bustling realm of real estate innovation, Homeshake, a startup born from the collaborative spirit within the University of Cincinnati's 1819 Innovation Hub, stands as a testament to the power of community support in entrepreneurial endeavors. Launched in 2020 by local visionaries Nick Rabin and Jonathan Bennie, Homeshake is a startup that sought to disrupt traditional real estate models.

3

Join the Information Security Outreach Roadshow

December 11, 2023

The UC Office of Information Security announces the Information Security Outreach Roadshows, interactive sessions designed to enhance cybersecurity skills university-wide. Starting January 2024, the program covers key topics like password management and phishing awareness, fostering a stronger digital security community at UC.

8

Ongoing quest for justice a life-changer for all parties

December 7, 2023

The Ohio Innocence Project and its student fellows, past and present, recently marked 20 years working to exonerate the wrongfully convicted. OIP co-founder and director Mark Godsey, as well as past OIP fellows and Cincinnati Law alumni, Eric Eckes, Law ’08, and Simar Khera, Law ’15, spoke about their shared experience and its life-changing impact.

10

UC Gardner Neuroscience Institute to lead new national stroke study

December 7, 2023

The UC Gardner Neuroscience Institute has received $19 million in federal funding from the National Institutes of Health to serve as the lead center for a Phase 2 clinical trial that will study the efficacy of a new monoclonal antibody treatment for patients ineligible for currently available treatments.